We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Labcyte and Thermo Fisher Scientific Collaborate to Provide siRNA Libraries in Acoustically Compatible Format
Product News

Labcyte and Thermo Fisher Scientific Collaborate to Provide siRNA Libraries in Acoustically Compatible Format

Labcyte and Thermo Fisher Scientific Collaborate to Provide siRNA Libraries in Acoustically Compatible Format
Product News

Labcyte and Thermo Fisher Scientific Collaborate to Provide siRNA Libraries in Acoustically Compatible Format


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Labcyte and Thermo Fisher Scientific Collaborate to Provide siRNA Libraries in Acoustically Compatible Format"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Labcyte Inc., has announced that Thermo Fisher Scientific, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo® qualified source plates.

This format enables customers to use the Echo liquid handler to transfer RNAi reagents during experiments, eliminating manual handling, reducing volumes, lowering costs and decreasing the risk of contamination.

The Echo liquid handler, used in scientific research and drug discovery, uses acoustic energy to move fluids without physical contact with the sample. There are no pipette tips, pin tools or nozzles involved.

This “touchless” dispensing eliminates the possibility of contaminating the RNAi stocks and allows for easy preparation of assay-ready plates. It also reduces costs associated with laboratory consumables and reduces labor by making the process more efficient.

“Our revolutionary instruments allow users to significantly lower transfer volumes, leading to dramatic reductions in cost,” said Mark Fischer-Colbrie, CEO and president of Labcyte.

Fischer-Colbrie continued, “Researchers show that low-volume siRNA transfections using acoustic transfer are equal or superior to those obtained with traditional liquid handlers. Cross-contamination is eliminated and transfection rates improve. Costs are further reduced with the elimination of disposable pipettes.”

Mike Deines, global director of marketing for Thermo Scientific genomics products, added, “We are delighted to provide our customers with the option to have our siRNA libraries delivered in Echo qualified format. Our customers have expressed a strong desire for acoustic transfer technology for siRNA libraries, and our collaboration with Labcyte has helped to bring a high-quality product to market quickly.”

One of the first customers to receive Thermo Scientific siRNA reagents in the Echo qualified plates is Dr. Spiros Linardopoulos, team leader in the Breakthrough Breast Cancer Research Centre, Cancer Therapeutics Unit, at the Institute of Cancer Research in London.

"Having siRNAs in Echo qualified plates offers us greater flexibility, total control of the remaining volume at any time and reduced risk of contamination,” said Dr. Linardopoulos. “We are very pleased to receive our libraries in this format.”

Additionally, researchers at Southern Research Institute, a not-for-profit drug discovery organization located in Birmingham, Alabama, have developed strategies for siRNA high throughput screening using Echo technology to transfer siRNAs to assay plates.

“Echo liquid handlers are advancing drug discovery efforts across a wide range of genomic and cell-based applications,” said Fischer-Colbrie.

Fischer-Colbrie continued, “Our unique technology enables techniques that were previously impossible and is opening the door to new biologic and small-molecule therapies. We are pleased to be working with Thermo Fisher Scientific in this joint effort.”

Advertisement